Tivic Health Systems Inc.

Company Overview

Business Model: Tivic Health Systems, Inc. is a diversified therapeutics company focused on harnessing the immune and autonomic nervous systems to treat disease. Its bioelectronic program develops non-invasive medical devices, currently offering ClearUP Sinus Pain Relief for sinus pain and congestion, and advancing non-invasive cervical vagus nerve stimulation (ncVNS) for neurologic, cardiac, and autonomic-related diseases. The biologic program, recently expanded, focuses on immunotherapeutics, with the lead product candidate being Entolimod, a late-stage Toll-like Receptor 5 (TLR5) agonist for acute radiation syndrome (ARS).

Market Position: ClearUP Sinus Pain Relief is the first FDA-approved bioelectronic treatment for its indications, available over-the-counter. While it holds a novel position in the non-drug category, it currently has a small market share compared to established pharmaceutical options. The company's market research identifies a $6 billion addressable market for ClearUP under current FDA approvals, extensible to $9.1 billion with adjacent indications. The broader vagus nerve stimulation (VNS) market is projected to reach $21 billion in the next five years, growing at a 10.6% compounded annual growth rate. The ARS market, targeted by Entolimod, is estimated at $5.2 billion in 2024, with projections to reach $7.3 billion by 2031. Entolimod has received FDA Fast Track and Orphan Drug designations.

Recent Strategic Developments:

• Biologics Program Expansion: In February 2025, Tivic Health Systems, Inc. acquired worldwide exclusive license rights from Statera Biopharma, Inc. for the late-stage TLR5 agonist Entolimod to treat ARS. This includes an exclusive option to license five additional indications and the second-generation product candidate, Entolasta. Michael Handley was appointed Chief Operating Officer and President of Tivic Biopharma to lead this new division.
• ncVNS Clinical Advancement: In May 2024, the company announced positive final results from a pilot research study with Feinstein Institute for the Bioelectronic Medicine at Northwell Health, demonstrating significant impact on clinical biomarkers related to vagus nerve activity and brain function. A second collaborative study with Feinstein Institute for the Bioelectronic Medicine at Northwell Health was initiated in May 2024 to optimize ncVNS device parameters, with enrollment completed in November 2024 and full results anticipated in Q2 2025.
• Commercial Strategy Development: In September 2024, Tivic Health Systems, Inc. partnered with Fletcher Spaght, Inc. to conduct a comprehensive market assessment for its ncVNS technology, identifying over 10 potential market applications, each with over $1 billion in market potential.
• Operational Streamlining: In August 2024, the Fulfillment Services Agreement with ALOM Technologies Corporation was terminated, and the company transitioned to third-party logistics and established in-house assembly and testing capabilities to reduce costs.
• Capital Raising & Corporate Actions: In May 2024, the company raised approximately $3.3 million net proceeds from a registered public offering of common stock and warrants. In September 2024, an Equity Distribution Agreement with Maxim Group LLC was established, allowing for the sale of up to $10 million in common stock, yielding approximately $1.1 million net proceeds in 2024. In March 2025, a 1-for-17 reverse stock split was implemented. Also in March 2025, an Equity Purchase Agreement with Mast Hill Fund, L.P. was entered into, providing the right to sell up to $25 million in common stock over two years.

Geographic Footprint: Tivic Health Systems, Inc. currently generates 100% of its revenue from sales within the United States. ClearUP Sinus Pain Relief is available through online retailers and commercial distributors across the U.S. The company has limited experience operating outside the United States and has not secured sales internationally to date, having elected not to reinstate its EU CE Mark. The newly licensed Entolimod program, however, holds worldwide exclusive license rights.

Financial Performance

Revenue Analysis

Profitability Metrics (2024):

• Gross Margin: 0.26%
• Operating Margin: -725.77%
• Net Margin: -725.00%

Investment in Growth (2024):

• R&D Expenditure: $1.3 million (168.3% of revenue)
• Capital Expenditures: $0 million
• Strategic Investments:
  • Acquisition of worldwide exclusive license rights to Entolimod from Statera Biopharma, Inc. for $300,000 in cash and $1.2 million in stock consideration (February 2025).
  • Commitments for ncVNS technology development: $171,000 remaining as of December 31, 2024, with $86,000 paid in March 2025 and the remainder expected in Q2 2025.

Product Line Analysis

ClearUP Sinus Pain Relief

Financial Performance:

• Revenue: $0.8 million (-33.7% YoY)
• Gross Profit: $0.0 million (-99.3% YoY)
• Key Growth Drivers: The decrease in revenue was primarily due to a 41% decrease in overall unit sales, largely attributed to a reduction in marketing spend. Gross profit was significantly impacted by $354,000 in inventory reserves recorded in 2024 (compared to $32,000 in 2023) and $21,000 in disposal costs related to a logistics provider change. The company expects reduced variable costs going forward due to supply chain optimization.

Product Portfolio:

• ClearUP Sinus Pain Relief: A patented, handheld neuromodulation device using ultra-low current electrical waves to relieve sinus pain and congestion symptoms. It is FDA-approved for temporary relief of sinus pain associated with allergic rhinitis and moderate to severe congestion.
• Ancillary products: Includes accessories and accelerated shipping services.

Market Dynamics:

• Competitive Positioning: ClearUP is a novel offering in the non-drug category, leveraging its first-to-market FDA approval for bioelectronic treatment of its indications. It competes against a wide array of over-the-counter pharmaceutical treatments (e.g., analgesics, antihistamines, decongestants) and other non-pharmaceutical options (e.g., nasal irrigation).
• Customer Insights: A 2023 study indicated that 58% of U.S. adults experiencing inflammation-related symptoms try to avoid medication. The market opportunity for ClearUP is estimated at $6 billion under current FDA approvals, with potential expansion to $9.1 billion with additional FDA review for closely adjacent indications like migraine.

Sub-segment Breakdown:

• Direct-to-consumer: $0.7 million revenue (-39% YoY), with approximately 3,100 units sold in 2024.
• Reseller: $0.2 million revenue (-21% YoY), with approximately 1,300 units sold in 2024. Average reseller channel selling prices increased by 23% in 2024 due to the introduction of a more profitable channel.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: None.
• Dividend Payments: Tivic Health Systems, Inc. has never declared or paid cash dividends on its common stock and does not anticipate doing so in the foreseeable future, intending to retain earnings for business operations and product offerings.
• Dividend Yield: 0%
• Future Capital Return Commitments: None disclosed.

Balance Sheet Position (as of December 31, 2024):

• Cash and Equivalents: $2.0 million
• Total Debt: $0 million (no long-term debt or capitalized operating lease liabilities)
• Net Cash Position: $2.0 million
• Credit Rating: Not disclosed.
• Debt Maturity Profile: Not applicable as no significant debt.

Cash Flow Generation (2024):

• Operating Cash Flow: -$5.7 million
• Free Cash Flow: -$5.7 million (Operating Cash Flow less Capital Expenditures of $0 million)
• Cash Conversion Metrics: The company experienced negative operating cash flow, indicating that operations did not generate sufficient cash to cover expenses.

Operational Excellence

Production & Service Model: The ClearUP device is manufactured using conventional, off-the-shelf electronic components. The company holds ISO 13485 certification, re-certified in 2023 and valid until Q4 2026, which validates its internal processes for FDA 21 CFR Part 820 compliance.

Supply Chain Architecture: Key Suppliers & Partners:

• Electronic Components: Future Electronics, Inc. (global distributor), primarily sourced from China.
• Manufacturing Partners: Plastic enclosure components and sub-assemblies are produced in China.
• Logistics: Third-party logistics and storage services from alternate suppliers (following termination of ALOM Technologies Corporation agreement in August 2024).
• Internal Capabilities: Established in-house assembly and testing capabilities.

Facility Network:

• Manufacturing: Electronic components are assembled, tested, warehoused, and distributed from North America.
• Research & Development: Limited in-house research facilities, supplemented by collaborations with institutions like Feinstein Institute for the Bioelectronic Medicine at Northwell Health.
• Distribution: Utilizes third-party logistics and storage services in North America.

Operational Metrics: No specific capacity utilization, efficiency measures, or quality indicators beyond ISO certification were disclosed.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Through the company's own website, tivichealth.com.
• Channel Partners: Major online retailers and commercial distributors.
• Digital Platforms: Amazon, McKesson, Optum Store, Walmart, Target, Best Buy, and FSA/HSA Store.

Customer Portfolio: Enterprise Customers:

• Commercial Distributors: McKesson-affiliate Simply Medical, Cardinal Health, AmerisourceBergen.
• Customer Concentration: In 2024, one customer accounted for 95% of accounts receivable and 18% of total revenue. In 2023, one customer accounted for 81% of accounts receivable and 20% of total revenue.

Geographic Revenue Distribution:

• United States: 100% of total revenue for both 2024 and 2023.
• Growth Markets: The company has limited experience operating outside the U.S. and has not yet targeted international markets for sales.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The sinus, cold, and allergy market is characterized by large, established players, predominantly offering pharmaceutical solutions. Bioelectronic medicine is an emerging market segment. The vagus nerve stimulation (VNS) market is projected to grow significantly, reaching $21 billion in the next five years with a 10.6% CAGR. The acute radiation syndrome (ARS) market is estimated at $5.2 billion in 2024, with growth to $7.3 billion by 2031, driven by global concerns over nuclear emergencies and advancements in radiation countermeasures.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors (ClearUP):

• Pharmaceuticals: GlaxoSmithKline, Bayer, and Johnson & Johnson (offering analgesics, antihistamines, oral/intranasal decongestants, intranasal glucocorticoids).
• Non-drug products: NeilMed, Rhinosystems Inc., SoundHealth, and Vapore LLC (offering nasal irrigation and other bioelectronic devices).

Primary Competitors (TLR5 Program - Entolimod):

• FDA-approved drugs for Hematopoietic Syndrome of Acute Radiation Syndrome (HS-ARS): filgrastim (Neupogen), peg-filgrastim (Neulasta), sargramostim (Leukine), and romiplostim (NPLATE).
• Other companies developing radiation countermeasures: Aeolus Pharmaceuticals, Araim Pharmaceuticals, Inc., Cellerant Therapeutics, Inc., Humanetics Corporation, Neumedicines, Inc., Pluristem Therapeutics, Inc, RxBio, Inc., and Soligenix, Inc.

Emerging Competitive Threats: New entrants, disruptive technologies, and alternative solutions in the evolving bioelectronic and biopharmaceutical sectors.

Competitive Response Strategy: For ClearUP, the strategy involves leveraging its novel product offering, evidence-based clinical research, and positive consumer acceptance. For ncVNS, the focus is on developing a superior non-invasive technology. For Entolimod, the company highlights its fundamental properties for prevention and treatment of ARS, including hematopoietic and gastrointestinal protection, and its potential for improved survival rates when used with existing compounds.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics: The company faces risks from unproven clinical and consumer acceptance of its new technologies, particularly in the emerging bioelectronic medicine segment. Operating results may be volatile due to market receptiveness, intrinsic variability in clinical trials, global supply chain disruptions, demand fluctuations, and delays in new technology introduction. Technology Disruption: There is a risk that the company's technology may not adapt to evolving user requirements or emerging treatment standards, and microcurrent/neuromodulation therapies may not become standard of care. Customer Concentration: In 2024, one customer accounted for 95% of accounts receivable and 18% of total revenue, indicating a concentration risk.

Operational & Execution Risks

Supply Chain Vulnerabilities: The company relies on third-party suppliers and manufacturers, with electronic components primarily sourced from China. Past disruptions due to global shortages and COVID-19 resurgence in China have impacted supply. Lead times can vary, and some components have limited sources, posing risks of increased costs, delays, or production slowdowns. Geographic Concentration: Manufacturing of plastic components in China and assembly/testing/distribution in North America exposes the company to risks from U.S.-China trade relations, tariffs, and regulatory changes (e.g., Uyghur Forced Labor Prevention Act, export restrictions on gallium and germanium). Capacity Constraints: While current capacity is believed to be sufficient after transitioning to new logistics providers and establishing in-house assembly, unforeseen demand spikes or supply issues could lead to constraints.

Financial & Regulatory Risks

Market & Financial Risks: Tivic Health Systems, Inc. has a history of net losses ($5.7 million in 2024, $8.2 million in 2023) and an accumulated deficit of $43.5 million as of December 31, 2024. These conditions raise substantial doubt about its ability to continue as a going concern. The company anticipates needing additional capital, which could dilute existing shareholder ownership. Significant cash expenditures are expected for the Statera Biopharma, Inc. license and ncVNS development. Inflationary pressures could adversely affect operating results. Credit & Liquidity: As of December 31, 2024, cash and equivalents were $2.0 million, with working capital of $2.4 million. The company relies on equity financings, including a recent Equity Purchase Agreement with Mast Hill Fund, L.P. for up to $25 million, to fund operations. Regulatory & Compliance Risks:

• Medical Devices: ClearUP is a U.S. FDA Class II medical device. Evolving regulatory standards for bioelectronic treatments could require additional clearances or approvals. The company elected not to incur costs for reinstating its EU CE Mark, limiting international market access.
• Biopharmaceuticals: The newly licensed Entolimod program is subject to extensive FDA regulations (FD&C Act, BLA process, preclinical/clinical testing, GLP, IND, IRB, cGMP). The company plans to utilize the FDA Animal Rule for Entolimod's biodefense indication, a pathway with limited prior use and for which the company has limited experience.
• Other Regulations: Subject to federal and state fraud and abuse laws, patient data privacy and security laws (HIPAA, HITECH, CCPA, CPRA, GDPR), and consumer protection laws.

Geopolitical & External Risks

Geopolitical Exposure: Reliance on foreign countries, particularly China, for component sourcing exposes the company to risks from changes in international relations, trade policies, tariffs, and export restrictions. Trade Relations: Changes in U.S. trade policy, including tariffs and sanctions, could adversely affect the business, especially given its supply chain dependencies. Sanctions & Export Controls: The company is subject to U.S. export control and import laws, sanctions, embargoes, and anti-corruption laws (e.g., FCPA). Geopolitical conflicts (e.g., Russia-Ukraine, Israel-Hamas) could lead to market disruptions and impact the ability to obtain additional funding.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• Bioelectronic Medicine: Focus on neuromodulation, specifically non-invasive peripheral nerve stimulation (ClearUP) and non-invasive cervical vagus nerve stimulation (ncVNS).
• Immunotherapeutics: Development of Toll-like Receptor 5 (TLR5) agonists (Entolimod, Entolasta). Innovation Pipeline:
• ncVNS: Currently undergoing clinical evaluation in partnership with Feinstein Institute for the Bioelectronic Medicine at Northwell Health, with a second study focused on optimizing stimulation parameters. Disease-specific trials are planned for 2025.
• Entolimod: Immediate focus on validation of the manufacturing process, including first lot manufacturing and bioequivalency testing, sufficient for a Biologics License Application (BLA) submission to the FDA.

Intellectual Property Portfolio:

• Patent Strategy: Pursues broad protection for key technologies, supplemented by additional filings covering conceptual methods, specific product aspects, and forward-looking applications. Engages in strategic analysis of owned patent assets.
• Patent Holdings:
  • Bioelectronic: 16 issued patents (U.S. and abroad), 11 pending patents (U.S. and abroad).
  • TLR5 Program: Over 60 active patents and patents pending.
• Licensing Programs: Acquired worldwide exclusive license rights to Entolimod from Statera Biopharma, Inc.
• IP Litigation: Not currently a party to any material IP litigation.

Technology Partnerships:

• Strategic Alliances: Feinstein Institute for the Bioelectronic Medicine at Northwell Health for ncVNS clinical validation and optimization studies.
• Research Collaborations: Not explicitly detailed beyond Feinstein Institute for the Bioelectronic Medicine at Northwell Health.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The company's executive officers are employed "at will." The recent appointment of Michael Handley as Chief Operating Officer and President of Tivic Biopharma is a key step in integrating the new biopharmaceutical assets.

Board Composition: The Board of Directors consists of four members: Jennifer Ernst, Sheryle Bolton, Christina Valauri, and Dean Zikria. Sheryle Bolton serves as Chair of the Board and is designated as an "audit committee financial expert." Dean Zikria, Sheryle Bolton, and Christina Valauri are independent directors. The Board is divided into three staggered classes, with terms expiring in 2025, 2026, and 2027. The Board has an Audit and Risk Committee, a Compensation Committee, and a Nominations and Corporate Governance Committee, each with independent directors.

Human Capital Strategy

Workforce Composition:

• Total Employees: 7 full-time employees and 2 contractors as of December 31, 2024.
• Geographic Distribution: Headquartered in Fremont, California.
• Skill Mix: Not explicitly detailed, but the company relies heavily on third-party service providers for specialized functions (e.g., marketing, manufacturing, clinical research, finance, legal).

Talent Management: Acquisition & Retention: The company utilizes equity incentive plans to attract, retain, and motivate employees, consultants, and directors. It faces significant competition for skilled personnel in areas such as marketing, product development, regulatory, clinical, quality, logistics, and finance. Employee Value Proposition: Not explicitly detailed.

Diversity & Development: Not explicitly detailed.

Environmental & Social Impact

Environmental Commitments:

• Supply Chain Sustainability: The company relies on its outsourced design and manufacturing partners to assist in maintaining compliance with applicable environmental laws and regulations.

Social Impact Initiatives: No specific social impact initiatives were disclosed.

Business Cyclicality & Seasonality

Demand Patterns: The company acknowledges that its operating results may fluctuate due to various factors, including seasonal variations in demand for its technology. Economic Sensitivity: The business is sensitive to economic uncertainty and capital markets disruption, which can be impacted by geopolitical instability, inflation, and interest rate changes. Industry Cycles: Not explicitly detailed.

Planning & Forecasting: The company finds it difficult to accurately forecast revenues or financial results due to geopolitical issues, inflation, interest rate changes, and the potential for a recession.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations:

• Medical Devices: ClearUP is regulated as a U.S. FDA Class II medical device, with 510(k) and De Novo clearances. The company adheres to Quality System Regulation (QSR/cGMP) requirements, including design, testing, control, documentation, and post-market surveillance (MDR). Labeling and promotional activities are subject to FDA and Federal Trade Commission (FTC) scrutiny, prohibiting off-label promotion.
• Biopharmaceuticals: The newly licensed Entolimod program is subject to the Federal Food, Drug, and Cosmetic Act (FD&C Act), requiring preclinical testing (GLP), Investigational New Drug (IND) application, Institutional Review Board (IRB) approval, and a Biologics License Application (BLA) for marketing approval. The company intends to utilize the FDA Animal Rule for Entolimod's biodefense indication. Entolimod has received Fast Track and Orphan Drug designations.
• Other Healthcare Laws: Subject to federal and state fraud and abuse laws (anti-kickback, self-referral, false claims, physician payment transparency), patient data privacy and security laws (HIPAA, HITECH, CCPA, CPRA, GDPR), and consumer protection laws. International Compliance: The company's EU CE Mark Certificate became inactive in September 2024 due to changes in European Union Medical Device Requirements, and the company elected not to incur costs for reinstatement. Separate regulatory approvals would be required for international markets.

Trade & Export Controls:

• Export Restrictions: Subject to U.S. Export Administration Regulations, U.S. Customs regulations, and economic/trade sanctions (OFAC).
• Sanctions Compliance: Compliance with anti-corruption laws (FCPA, U.S. domestic bribery statute, U.S. Travel Act, USA PATRIOT Act) is required, especially when engaging third parties for international activities.
• Geopolitical Impact: Changes in U.S.-China relations, tariffs, and export restrictions (e.g., Uyghur Forced Labor Prevention Act, gallium/germanium export controls) could impact operations.

Legal Proceedings: Tivic Health Systems, Inc. is not currently a party to any material legal proceedings.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: 0% for both 2024 and 2023, primarily due to the establishment of a full valuation allowance on its deferred tax assets.
• Geographic Tax Planning: Files U.S. Federal and state (California) tax returns.
• Tax Reform Impact: A Section 382 study was performed in 2024, which identified ownership changes that resulted in some tax attributes expiring due to limitations. As of December 31, 2024, the company had federal net operating loss carryforwards of approximately $35.5 million (expiring from 2036, with $35.1 million carried forward indefinitely) and state net operating loss carryforwards for California of approximately $2.6 million (expiring from 2031). Federal and state research and development credit carryforwards were $26,000 and $336,000, respectively.

Insurance & Risk Transfer

Risk Management Framework: Tivic Health Systems, Inc. maintains insurance coverage for its assets, operations, and employees. However, this coverage is subject to limits and exclusions and may not be sufficient to cover all risks, including potential litigation. There is no assurance that adequate insurance will be available in the future or at commercially justifiable premiums.